주식 거래정지, 소송 등 인보사 사태 파장...코오롱 "조직,은폐 없다"<br /><br />Yeserday, the government revoked the license for a gene therapy treatment called Invossa, sending the stock price of the companies that developed and produced it plunging by the daily limit.<br />Shares of the manufacturer, Kolon Life Science, are back on the market, but its subsidiary, which developed the treatment, is still suspended.<br />Yoon Jung-min has the latest. <br />The Korea Exchange said it will continue suspending trading for Kolon TissueGene until it finds it appropriate to consider listing the company again.<br />On Tuesday, the trading for both Kolon TissueGene and Kolon Life Science was halted after the government canceled the license of their gene therapy drug Invossa for mislabeling a cell ingredient. Manufacturer Kolon Life Science even faces criminal charges after the investigation revealed the gene therapy treatment used kidney cells, not cartilage cells.<br />Kolon Life Science resumed trading on Wednesday, but its stock price plunged by more than 20 percent in the first two hours of trading.<br />Bio-industry pioneer Kolon is facing its worst crisis since it was founded 62 years ago. The government is considering taking back funding worth more than 6-point-8 million U.S. dollars,...which manufacturer Kolon Life Science has received since 2015.<br />Some 3-thousand-700 people are reported to have used the drug,... and many fear whether the drug could cause them harm. 244 patients have filed a lawsuit worth more than 2-million U.S. dollars against Kolon Life Science.<br />"The pain in my legs didn't get any better before or after the medication. It's rather more uncomfortable because I have to see a doctor and get other treatment.<br />Kolon Life Science, however, said they did not manipulate or cover up anything although there was some data lacking when the drug was under its approval review.<br />The company added it will further analyze the cell ingredient and cooperate with the drug safety ministry.<br />Yoon Jung-min, Arirang News. <br />
